Sugi Predict

Sugi Predict / Compounds / SCHEMBL2203246

SCHEMBL2203246

SCHEMBL2203246

CCOC(=O)c1cnc2c(Br)cccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSMD14 O00487 1/20 0.51
▸ MAOB P27338 3/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ NR1H4 Q96RI1 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ P2RY12 Q9H244 1/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ HPGDS O60760 1/20 0.44
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ CA14 Q9ULX7 1/20 0.44
▸ NPC1 O15118 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2201187 0.86 KDM4E (0.55) PSMD14MAOBCYP1A2NR1H4CYP2C9
SCHEMBL4155141 0.85 PSMD14 (0.50) PSMD14MAOBCYP1A2NR1H4CYP2C9
SCHEMBL4150906 0.85 MAOB (0.53) PSMD14MAOBCYP1A2NR1H4CYP2C9
SCHEMBL6537724 0.85 PSMD14 (0.50) PSMD14MAOBCYP1A2NR1H4CYP2C9
SCHEMBL20605105 0.84 PSMD14 (0.70) PSMD14KDM4EMAPK1L3MBTL1HPGDS
SCHEMBL4721861 0.84 HPGDS (0.64) PSMD14MAOBKMT2AHPGDSNPC1
SCHEMBL28234393 0.83 MAPT (0.51) PSMD14MAOBCYP1A2NR1H4CYP2C9
SCHEMBL4036100 0.82 CA12 (0.46) CYP1A2SMN1; SMN2KMT2AKDM4EMAPK1
SCHEMBL17375830 0.82 KMT2A (0.62) PSMD14MAOBP2RY12SMN1; SMN2KMT2A
SCHEMBL27773938 0.82 CCR1 (0.54) PSMD14MAOBCYP2C9CYP2C19SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234220-B2 Immunomodulatory compounds DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-02-25 — — US disclosed
EP-4358948-A1 TEAD INHIBITORS AND USES THEREOF Cedilla Therapeutics, Inc. (US) 2024-05-01 — — EP disclosed
US-11866435-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2024-01-09 — — US disclosed
EP-4292650-A2 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS Incyte Corporation (US) 2023-12-20 — — EP disclosed
CN-116514715-A Heterocyclic compounds as immunomodulators 因赛特公司 2023-08-01 — — CN disclosed
US-20230100875-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2023-03-30 — — US disclosed
US-20230053649-A1 TEAD INHIBITORS AND USES THEREOF CEDILLA THERAPEUTICS, INC. 2023-02-23 — — US disclosed
WO-2022272036-A1 TEAD INHIBITORS AND USES THEREOF CEDILLA THERAPEUTICS, INC. (US) 2022-12-29 — — WO disclosed
WO-2022272036-A1 TEAD INHIBITORS AND USES THEREOF CEDILLA THERAPEUTICS, INC. (US) 2022-12-29 — — WO disclosed
US-11535615-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2022-12-27 — — US disclosed
WO-2006103120-A2 NEW HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-ALZHEIMER AGENTS INSA ROUEN (FR) 2006-10-05 — — WO disclosed
EP-1243583-B1 HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS EISAI CO LTD (JP) 2005-09-28 — — EP disclosed
CN-1217936-C Heterocyclic compounds having sulfonic acid EISAI CO LTD (JP) 2005-09-07 — — CN disclosed
US-20050176712-A1 Integrin expression inhibitor EISAI CO., LTD. 2005-08-11 — — US disclosed
US-6787534-B2 SUBSTITUTED QUINOLINE AND ISOQUINOLINE ANTIANGIOGENIC AGENTS; SULFONYLUREAS EISAI CO., LTD. (JP) 2004-09-07 — — US disclosed
US-20040018192-A1 Integrin expression inhibitors EISAI CO., LTD. (JP) 2004-01-29 — — US disclosed
US-20030144507-A1 Sulfonamide-containing heterocyclic compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2003-07-31 — — US disclosed
CN-1414952-A Heterocyclic compounds having sulfonic acid EISAI CO LTD (JP) 2003-04-30 — — CN disclosed
EP-1258252-A1 INTEGRIN EXPRESSION INHIBITORS Eisai Co., Ltd. (JP) 2002-11-20 — — EP disclosed
EP-1243583-A1 HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS Eisai Co., Ltd. (JP) 2002-09-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176712-A1 Integrin expression inhibitor ITGB5, ITGB1, ITGB2 PSMD14 3476/4885MAOB 2321/4885CYP1A2 3959/4885
US-20230100875-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS PSMD14 2922/4885MAOB 592/4885CYP1A2 330/4885
US-11535615-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS PSMD14 2922/4885MAOB 592/4885CYP1A2 330/4885
US-12234220-B2 Immunomodulatory compounds CRBN, CD47, CD58 PSMD14 1050/4885MAOB 3653/4885CYP1A2 4783/4885
US-11866435-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS PSMD14 2922/4885MAOB 592/4885CYP1A2 330/4885
US-20040018192-A1 Integrin expression inhibitors ITGB1, ITGB4, ITGB5 PSMD14 3191/4885MAOB 2701/4885CYP1A2 4021/4885
US-20030144507-A1 Sulfonamide-containing heterocyclic compounds SLC5A2, SLC5A1, CBR3 PSMD14 3286/4885MAOB 1112/4885CYP1A2 417/4885
US-20230053649-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 PSMD14 1048/4885MAOB 651/4885CYP1A2 1435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.